Boston Scientific Corporation (LON: 0HOY)
Market Cap | 120.04B |
Revenue (ttm) | 11.87B |
Net Income (ttm) | 1.34B |
Shares Out | n/a |
EPS (ttm) | 0.90 |
PE Ratio | 89.73 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 133,002 |
Average Volume | 13,242 |
Open | 101.25 |
Previous Close | 101.01 |
Day's Range | 100.49 - 101.63 |
52-Week Range | 47.37 - 101.63 |
Beta | 0.80 |
RSI | 77.62 |
Earnings Date | Jan 31, 2025 |
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, c... [Read more]
Financial Performance
In 2023, Boston Scientific's revenue was $14.24 billion, an increase of 12.29% compared to the previous year's $12.68 billion. Earnings were $1.57 billion, an increase of 144.55%.
Financial numbers in USD Financial StatementsNews
Top 4 Health Care Stocks You May Want To Dump In Q1
As of Jan. 21, 2025, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Boston Scientific (BSX) Receives Preliminary Approval for Shareholder Derivative Settlement
Boston Scientific (BSX) Receives Preliminary Approval for Shareholder Derivative Settlement
Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation
First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field Abl...
Boston Scientific Jumps Ahead of Earnings
Boston Scientific Corporation (BSX) shares rise on acquisitions – earnings due in early February.
Boston Scientific Standing Apart As A Rare Med-Tech Growth Story
We have the largest venture portfolio in medtech, says Boston Scientific CEO Mike Mahoney
Boston Scientific Chair and CEO Mike Mahoney joins 'Mad Money' host Jim Cramer at the JPMorgan Healthcare COnference to talk its outlook for 2025, its venture portfolio, and more.
Stocks on the move: Delta, Constellation Energy, Wynn, Sweetgreen and Boston Scientific
The Investment Committee discuss some stocks on the move today.
Stocks on the move: Delta, Constellation Energy, Wynn, Sweetgreen and Boston Scientific
The Investment Committee discuss some stocks on the move today.
Boston Scientific Completes Acquisition of Bolt Medical, Bolstering Cardiovascular Portfolio
Boston Scientific Completes Acquisition of Bolt Medical, Bolstering Cardiovascular Portfolio
Mixed gains/losses in the major indices
The major US indices are ending the day mixed with the Dow and S&P higher, and the Nasdaq and Russell 2000 lower. Trading conditions were up and down volatile. Tomorrow the stock markets will be close...
Final Trades: Apollo, UnitedHealth, Boston Scientific and the IYF
The Investment Committee give you their top stocks to watch for the second half.
Final Trades: Apollo, UnitedHealth, Boston Scientific and the IYF
The Investment Committee give you their top stocks to watch for the second half.
J&J Falls — While Boston Scientific, Medtronic Pop — After Strokes Sideline A Key Product
Johnson & Johnson stock skidded Wednesday after the company temporarily paused sales of its pulsed field ablation system.
Boston Scientific Expands Cardiovascular Treatment Portfolio With $440 Million+ Bolt Medical Deal
On Wednesday, Boston Scientific Corporation (NYSE: BSX) agreed to acquire Bolt Medical, Inc. , the developer of an intravascular lithotripsy (IVL) advanced laser-based platform for coronary and perip...
Boston Scientific Expands Cardiovascular Treatment Portfolio With $440 Million+ Bolt Medical Deal
On Wednesday, Boston Scientific Corporation BSX agreed to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy (IVL) advanced laser-based platform for coronary and peripheral arte...
Boston Scientific to Acquire Bolt Medical for $443 Million in Expansion of Cardiovascular Portfolio
Boston Scientific to Acquire Bolt Medical for $443 Million in Expansion of Cardiovascular Portfolio
Boston Scientific (BSX) Reaches New High Following Acquisition Announcement
Boston Scientific (BSX) Reaches New High Following Acquisition Announcement
Boston Scientific Surges Into Buy Zone On $900 Million Takeover Of Bolt Medical
Boston Scientific stock popped Wednesday after the medtech giant agreed to full acquire Bolt Medical for up to $900 million.
Boston Scientific announces acquisition of the remaining stake in Bolt Medical
Boston Scientific (BSX) announced on Wednesday the acquisition of the ~74% stake in Bolt Medical that the medical devices company does not already own.
Boston Scientific Announces Agreement to Acquire Bolt Medical, Inc.
Acquisition to expand cardiovascular portfolio with complementary and differentiated calcium modification platform, furthering company's strategy to address coronary and peripheral disease MARLBOROUGH...
Healthcare sector's 2024 gainers and losers: Intuitive Surgical, Boston Scientific tops chart
Learn about the performance of the healthcare sector in 2024, top performers, bottom performers, analyst expectations, and quantitative measures.
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.
Here's How Much $1000 Invested In Boston Scientific 10 Years Ago Would Be Worth Today
Boston Scientific (NYSE: BSX) has outperformed the market over the past 10 years by 9.12% on an annualized basis producing an average annual return of 20.37%. Currently, Boston Scientific has a marke...
Boston Scientific Corp (BSX) Announces Participation in J.P. ...
Boston Scientific Corp (BSX) Announces Participation in J.P. Morgan Healthcare Conference and Q4 2024 Results Call
Boston Scientific Announces Participation in the J.P. Morgan Healthcare Conference and Conference Call Discussing Fourth Quarter 2024 Results
MARLBOROUGH, Mass. , Jan. 2, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 43rd Annual J.P.